医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s announces the Launch of Paricalcitol Capsules

2014年06月25日 PM11:22
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of ZEMPLAR® (Paricalcitol) Capsules in the US market on June 24, 2014, following the approval by the United States Food & Drug Administration (USFDA).

The ZEMPLAR® brand and generic had U.S. sales of approximately $109.6 Million MAT for the most recent twelve months ending in March 2014 according to IMS Health*.

Dr. Reddy’s Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are available in bottle counts of 30.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com

ZEMPLAR® is a registered trademark of AbbVie INC.

*IMS National Sales Perspectives: Retail and Non-Retail MAT March 2014

CONTACT

Dr. Reddy’s
Media:
SVS
Chowdary at
chowdaryl@drreddys.com
/ +91-40- 49002448

or
Investors
and Financial Analysts:

Kedar Upadhye at kedaru@drreddys.com
/ +91-40-66834297

Saunak Savla at saunaks@drreddys.com
/ +91-40-49002135

Milan Kalawadia (USA) at mkalawadia@drreddys.com
/ +1-609-375-9831

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • ソウルバイオシスがウイルスを10分で死滅させるポータブル型「フォトン・スタンド」表面殺菌ユニットを開発
  • 患者安全運動財団が2020年人道賞の受賞者を発表
  • Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients
  • Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)
  • No Dogs Left Behind Meat Market Survivors Coming Home